|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
EP1648507B1
(en)
|
2003-07-24 |
2017-01-25 |
Innate Pharma S.A. |
Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
|
|
US20070231322A1
(en)
*
|
2004-04-30 |
2007-10-04 |
Innate Pharma, S.A. |
Compositions and Methods for Treating Proliferative Disorders Such as Nk-Type Ldgl
|
|
CN1997670B
(zh)
|
2004-07-01 |
2014-04-30 |
诺和诺德公司 |
人类抗-kir抗体
|
|
PT2287195T
(pt)
*
|
2004-07-01 |
2019-07-29 |
Novo Nordisk As |
Anticorpos de recetor de nk de pan-kir2dl e a sua utilização em diagnóstico e terapêutica
|
|
EP2921500B1
(en)
|
2004-07-10 |
2023-08-30 |
The Institute for Cancer Research |
Genetically modified human natural killer cell lines
|
|
CA2589034C
(en)
*
|
2004-11-02 |
2016-05-31 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for treating hyperproliferative disorders
|
|
EP1835929B8
(en)
*
|
2005-01-06 |
2016-07-27 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
|
EP1835937B1
(en)
|
2005-01-06 |
2012-04-11 |
Novo Nordisk A/S |
Compositions and methods for treating viral infection
|
|
CN104829720B
(zh)
|
2005-01-06 |
2019-01-01 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
|
WO2007042573A2
(en)
*
|
2005-10-14 |
2007-04-19 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
|
US20100189723A1
(en)
|
2007-01-11 |
2010-07-29 |
Peter Andreas Nicolai Reumert Wagtmann |
Anti-kir antibodies, formulations, and uses thereof
|
|
WO2010065939A1
(en)
|
2008-12-05 |
2010-06-10 |
Indiana University Research & Technology Corporation |
Combination therapy to enhace nk cell mediated cytotoxicty
|
|
EP2808402A3
(en)
*
|
2008-12-29 |
2015-03-25 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Methods of predicting responsiveness to interferon treatment
|
|
KR20130033354A
(ko)
*
|
2010-02-08 |
2013-04-03 |
가부시키가이샤 니혼 바이오세라피 켄큐쇼 |
Ｎｋ세포 강화형 혈액제제의 제조 방법
|
|
CA2818684C
(en)
|
2010-11-22 |
2023-02-21 |
Innate Pharma Sa |
Nk cell modulating treatments and methods for treatment of hematological malignancies
|
|
AU2012260601B2
(en)
|
2011-05-25 |
2018-02-01 |
Innate Pharma, S.A. |
Anti-KIR antibodies for the treatment of inflammatory disorders
|
|
WO2012175613A1
(en)
|
2011-06-21 |
2012-12-27 |
Innate Pharma |
NKp46-MEDIATED NK CELL TUNING
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
EP2782931B1
(en)
*
|
2011-11-23 |
2016-12-14 |
F. Hoffmann-La Roche AG |
Cd40l expressing mammalian cells and their use
|
|
CA2881765C
(en)
*
|
2012-09-19 |
2024-02-13 |
Innate Pharma |
Kir3dl2 binding agents
|
|
EP2904011B1
(en)
|
2012-10-02 |
2017-08-23 |
Bristol-Myers Squibb Company |
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
|
|
WO2015069785A1
(en)
|
2013-11-06 |
2015-05-14 |
Bristol-Myers Squibb Company |
Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
|
|
JP6654781B2
(ja)
*
|
2014-08-29 |
2020-02-26 |
国立大学法人北海道大学 |
Ｋｉｒ２ｄｓ１に対するモノクローナル抗体
|
|
ES2772307T3
(es)
|
2014-10-28 |
2020-07-07 |
Childrens Univ Hospital Tuebingen |
Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir
|
|
JP6895380B2
(ja)
|
2015-02-06 |
2021-06-30 |
ナショナル ユニバーシティ オブ シンガポール |
治療免疫細胞の有効性を改良するための方法
|
|
SG11201708223QA
(en)
|
2015-04-17 |
2017-11-29 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
RU2017142352A
(ru)
|
2015-05-06 |
2019-06-06 |
Снипр Текнолоджиз Лимитед |
Изменение популяций микроорганизмов и модификация микробиоты
|
|
KR101997241B1
(ko)
|
2015-05-21 |
2019-07-09 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
|
CN116196426A
(zh)
|
2015-07-16 |
2023-06-02 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
HRP20220436T1
(hr)
*
|
2015-11-03 |
2022-05-27 |
Janssen Biotech, Inc. |
Protutijela koja se specifično vežu na pd-1 i njihove uporabe
|
|
EP3371221A2
(en)
|
2015-11-07 |
2018-09-12 |
MultiVir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
JP7169195B2
(ja)
|
2016-05-20 |
2022-11-10 |
バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド |
癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
WO2018014001A1
(en)
|
2016-07-14 |
2018-01-18 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
|
BR112019006041A2
(pt)
|
2016-09-27 |
2019-09-03 |
Board Of Regents, The University Of Texas System |
métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
|
|
GB201616365D0
(en)
*
|
2016-09-27 |
2016-11-09 |
Helsingin Yliopisto |
Non-genetic modification of enveloped viruses
|
|
RU2755903C2
(ru)
|
2016-10-12 |
2021-09-22 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Способы и композиции для tusc2-иммунотерапии
|
|
AU2017345203B2
(en)
|
2016-10-21 |
2024-08-01 |
Innate Pharma |
Treatment with anti-KIR3DL2 agents
|
|
KR20190112263A
(ko)
|
2016-12-12 |
2019-10-04 |
멀티비르 인코포레이티드 |
암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
|
|
AU2018243754B2
(en)
|
2017-03-31 |
2025-04-10 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CA3057989C
(en)
|
2017-04-05 |
2023-03-21 |
Korea Research Institute Of Bioscience And Biotechnology |
Nk cell-activating fusion protein, nk cell, and pharmaceutical composition including same
|
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
US12116406B2
(en)
|
2017-05-26 |
2024-10-15 |
Fred Hutchinson Cancer Center |
Anti-CD33 antibodies and uses thereof
|
|
CN107261304A
(zh)
*
|
2017-06-05 |
2017-10-20 |
中国兽医药品监察所 |
一种奶牛的布鲁氏菌病免疫试剂盒及其应用
|
|
JP2020530291A
(ja)
|
2017-08-10 |
2020-10-22 |
ナショナル ユニバーシティ オブ シンガポール |
Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
|
|
WO2019075359A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
TRISPECIFIC PROTEINS AND METHODS OF USE
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
CN108060137B
(zh)
*
|
2017-12-26 |
2021-07-02 |
博生吉医药科技(苏州)有限公司 |
Il7和il21修饰的nk92细胞、制备方法及其应用
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
PT3749346T
(pt)
|
2018-02-08 |
2024-09-05 |
Dragonfly Therapeutics Inc |
Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
|
|
KR20200118824A
(ko)
|
2018-02-08 |
2020-10-16 |
드래곤플라이 쎄라퓨틱스, 인크. |
자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
|
|
CA3091424A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
AU2019322487B2
(en)
|
2018-03-19 |
2024-04-18 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
WO2019185551A1
(en)
|
2018-03-25 |
2019-10-03 |
Snipr Biome Aps. |
Treating & preventing microbial infections
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
WO2019191676A1
(en)
|
2018-03-30 |
2019-10-03 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
SG11202010996QA
(en)
|
2018-05-23 |
2020-12-30 |
Nat Univ Singapore |
Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
SG11202101298XA
(en)
|
2018-08-08 |
2021-03-30 |
Dragonfly Therapeutics Inc |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
US12398402B2
(en)
|
2018-09-12 |
2025-08-26 |
Fred Hutchinson Cancer Center |
Reducing CD33 expression to selectively protect therapeutic cells
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
BR112021005769A2
(pt)
|
2018-09-25 |
2021-07-06 |
Harpoon Therapeutics Inc |
proteínas de ligação a dll3 e métodos de uso
|
|
AU2019408408A1
(en)
|
2018-12-21 |
2021-06-03 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
KR20220016156A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
|
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
CN111424012A
(zh)
*
|
2020-03-30 |
2020-07-17 |
威海市中心医院 |
一种nk细胞培养用的饲养细胞去增殖能力的处理方法
|
|
CA3177024A1
(en)
|
2020-05-06 |
2021-11-11 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and clec12a
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
CA3182579A1
(en)
|
2020-07-07 |
2022-01-13 |
Ugur Sahin |
Therapeutic rna for hpv-positive cancer
|
|
KR20230061430A
(ko)
|
2020-08-31 |
2023-05-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 면역요법
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022140755A1
(en)
*
|
2020-12-23 |
2022-06-30 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies
|
|
CA3196999A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Methods of treating tumors
|
|
SI4267105T1
(sl)
|
2020-12-28 |
2025-07-31 |
Bristol-Myers Squibb Company |
Sestave protiteles in načini njihove uporabe
|
|
US20240101673A1
(en)
|
2021-02-03 |
2024-03-28 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
MX2024000674A
(es)
|
2021-07-13 |
2024-02-07 |
BioNTech SE |
Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
|
|
MX2024004082A
(es)
|
2021-10-08 |
2024-04-18 |
3M Innovative Properties Company |
Montaje de troquel de ranura con rigidez ajustada, zona de extraccion reducida y estimacion de fuerza.
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
US20250051440A1
(en)
|
2021-12-14 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
|
EP4448761A1
(en)
|
2021-12-16 |
2024-10-23 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
CA3258064A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol Myers Squibb Co |
ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024026385A1
(en)
*
|
2022-07-28 |
2024-02-01 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies
|
|
TW202426486A
(zh)
*
|
2022-10-25 |
2024-07-01 |
日商第一三共股份有限公司 |
使用針對抑制型ｋｉｒ的促效劑的免疫排斥之迴避方法
|
|
IL321098A
(en)
|
2022-12-14 |
2025-07-01 |
Astellas Pharma Europe Bv |
Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
CN117883553B
(zh)
*
|
2024-01-12 |
2024-08-27 |
成都医学院 |
Pml-1蛋白在制备抑制细胞因子风暴的药物中的应用
|